<DOC>
	<DOCNO>NCT01698749</DOCNO>
	<brief_summary>This study undertaken determine effect intravitreal long act dexamethasone implant , ( Ozurdex® ) patient diabetic macular edema.Diabetic macular edema important cause visual impairment patient diabetes mellitus . Focal/ grid laser photocoagulation standard care management . Several adjunct include intravitreal corticosteroid , Pegabtanib Sodium , Ranibizumab , Bevacizumab , non-steroidal anti-inflammatory agent , corticosteroid , laser photocoagulation try . Intravitreal Triamcinolone Acetonide ( TA ) , water insoluble steroid , show reduce retinal thickness improve visual acuity . However , recurrence macular edema patient receive intravitreal TA major concern patient need multiple repeat injection short half life . A potent steroid , dexamethasone also try alternative TA macular edema ; however , short half life 3 hour prevents clinical application . In search ideal corticosteroid preparation , Dexamethasone Posterior Segment Drug Delivery System ( Dexamethasone DDS - Ozurdex® , Allergan Inc , Irvine , California ) recently develop . Promising result show certain patient retinal vein occlusion , uveitis receive intravitreal drug delivery system improvement visual acuity . The present study introduces novel concept use Ozurdex ® implant patient diabetic macular edema .</brief_summary>
	<brief_title>Effect Intravitreal Long Acting Dexamethasone Implant , Ozurdex Patients With Diabetic Macular Edema</brief_title>
	<detailed_description>This study undertaken determine effect intravitreal long act dexamethasone implant , ( Ozurdex® ) patient diabetic macular edema.Diabetic macular edema important cause visual impairment patient diabetes mellitus . Focal/ grid laser photocoagulation standard care management . Several adjunct include intravitreal corticosteroid , Pegabtanib Sodium , Ranibizumab , Bevacizumab , non-steroidal anti-inflammatory agent , corticosteroid , laser photocoagulation try . Intravitreal Triamcinolone Acetonide ( TA ) , water insoluble steroid , show reduce retinal thickness improve visual acuity . However , recurrence macular edema patient receive intravitreal TA major concern patient need multiple repeat injection short half life . A potent steroid , dexamethasone also try alternative TA macular edema ; however , short half life 3 hour prevents clinical application . In search ideal corticosteroid preparation , Dexamethasone Posterior Segment Drug Delivery System ( Dexamethasone DDS - Ozurdex® , Allergan Inc , Irvine , California ) recently develop . Promising result show certain patient retinal vein occlusion , uveitis receive intravitreal drug delivery system improvement visual acuity . The present study introduces novel concept use Ozurdex ® implant patient diabetic macular edema .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>The patient Type 1 Type 2 Diabetes Mellitus fulfil follow inclusion criterion shall enrol study : 1 . Patients Non Proliferative Diabetic retinopathy ( NPDR ) clinicaly significant macular edema ( CSME ) 2 . Patients Proliferative Diabetic Retinopathy ( PDR ) CSME proliferative component adequately treat laser photocoagulation 3 . Diabetic patient withcystoid macular edema 4 . Minimum central thickness OCT le 300 micron 1 . Patients history ocular hypertension glaucoma 2 . Patients medium haze pupillary nondilation allow good fundus photography , FFA OCT. 3 . Patients macular ischemia FFA</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Ozurdex</keyword>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Central macular thickness</keyword>
</DOC>